Concordance between measures of functioning, symptoms, and change: Examining the GAF, CGI-S, CGI-C, and PANSS

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 478-480

  Rabinowitz, Jonathan ^a   Levine, Stephen ^a   Martinez, Guadalupe ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b Janssen Cilag EMEA Belgium   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE; NEUROLEPTIC AGENT;

CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CORRELATION ANALYSIS; HUMAN; LETTER; MEDICAL RESEARCH; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SUICIDAL IDEATION; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 77955131760     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e7145f     Document Type: Letter

References (15)

1. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
2. Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31:2318-2325.
3. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79:231-238.
4. Levine SZ, Rabinowitz J, Engel R, et al. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res. 2008;98:318-322.
5. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-771.
6. Goldman HH. Do you walk to school, or do you carry your lunch? Psychiatr Serv. 2005;56:419.
7. Moos RH, Nichol AC, Moos BS. Global Assessment of Functioning ratings and the allocation and outcomes of mental health services. Psychiatr Serv. 2002;53:730-737.
8. Skodol AE, Link BG, Shrout PE, et al. The revision of axis V in DSM-III-R: should symptoms have been included? Am J Psychiatry. 1988;145:825-829.
9. Moos RH, McCoy L, Moos BS. Global Assessment of Functioning (GAF) ratings: determinants and role as predictors of one-year treatment outcomes. J Clin Psychol. 2000;56:449-461.
10. Roy-Byrne P, Dagadakis C, Unutzer J, et al. Evidence for limited validity of the revised Global Assessment of Functioning scale. Psychiatr Serv. 1996;47:864-866.
11. Niv N, Cohen AN, Sullivan G, et al. The MIRECC version of the Global Assessment of Functioning scale: reliability and validity. Psychiatr Serv. 2007;58:529-535.
12. Startup M, Jackson MC, Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol. 2002;41:417-422.
13. Napryeyenko O, Burba B, Martinez G, et al. Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures. J Clin Psychopharmacol. 2010;30:1-3.
14. Guy WB. Manual for the ECDEUAssessment Battery. 2nd ed. Chevy Chase, MD: National Institute of Mental Health; 1970.
15. Kolen MJ, Brennan RL. Test Equating, Scaling, and Linking: Methods and Practices. 2nd ed. New York, NY: Springer; 2004.